BeiGene, soon to be renamed BeOne Medicines Ltd., announced plans to present extensive data from its hematology portfolio at the upcoming European Hematology Association (EHA) Congress in Milan, Italy, June 12-15. The company will showcase 31 accepted abstracts, with four selected for oral presentations, highlighting its growing influence in the treatment of hematologic malignancies.
Expanding Hematology Portfolio
BeiGene's presentations will feature data from its FDA-approved BTK inhibitor BRUKINSA® (zanubrutinib) alongside two investigational pipeline assets – sonrotoclax, a next-generation BCL2 inhibitor, and BGB-16673, a BTK protein degrader. These three cornerstone therapies form what the company describes as a potentially best-in-class portfolio for treating B-cell malignancies.
"At EHA 2025, we'll share 31 accepted abstracts that highlight the progress of our hematology clinical development program and our commitment to targeted therapies that raise the standard of care," said Lai Wang, Ph.D., Global Head of R&D at BeiGene. "As BRUKINSA continues to expand its impact and our next-generation assets advance, we hope to transform the future of treatment for patients facing B-cell malignancies."
Next-Generation Pipeline Assets Show Promise
BeiGene's investigational therapies continue to demonstrate encouraging results in clinical trials. Both BGB-16673 and sonrotoclax have shown promising clinical activity and generally well-tolerated safety profiles across multiple B-cell malignancies.
The company's clinical development programs have enrolled more than 2,500 patients globally, with over 1,900 patients in sonrotoclax trials and more than 600 patients in BGB-16673 studies. These therapies are positioned to potentially play significant roles in treatment strategies for chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia (WM), and mantle cell lymphoma (MCL).
Key Presentations at EHA 2025
Four oral presentations will highlight BeiGene's most significant findings:
-
Two presentations will feature updated results from the ongoing Phase 1 CaDAnCe-101 study of BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL and patients with R/R WM, showing continued and promising early efficacy with a tolerable safety profile.
-
Two additional presentations will showcase updated Phase 1 results of sonrotoclax in combination with BRUKINSA in R/R CLL/SLL and R/R MCL, demonstrating deep and durable responses.
The sonrotoclax-BRUKINSA combination is currently being evaluated in two registrational trials: the Phase 3 fixed-duration CELESTIAL-TNCLL study in treatment-naïve CLL/SLL patients, which has completed enrollment, and the CELESTIAL-RRMCL study in patients with relapsed/refractory MCL, which is currently enrolling.
BeiGene will also present results from Arms C and D of the SEQUOIA study, which evaluated BRUKINSA in treatment-naïve CLL/SLL patients with del(17p) and BRUKINSA plus venetoclax in patients with TN CLL/SLL with del(17p) and/or TP53 mutation or without either mutation.
BRUKINSA's Established Position
BRUKINSA has established itself as a leading BTK inhibitor with the broadest label globally in its class. It is the only BTK inhibitor to provide the flexibility of once or twice daily dosing and has demonstrated superiority to another BTK inhibitor in a Phase 3 study.
The global BRUKINSA clinical development program has included approximately 7,100 patients enrolled across more than 35 trials in 30 countries. The therapy is now approved in more than 75 markets worldwide, with over 200,000 patients treated globally.
About the Investigational Therapies
Sonrotoclax (BGB-11417) is designed to block the B-cell lymphoma 2 (BCL2) protein, which helps cancer cells survive. As a BH3 mimetic, it mimics natural cell death signals and has shown potent and specific inhibition of BCL2 with a short half-life and no accumulation. The FDA has granted Fast Track Designation for sonrotoclax in treating adult patients with MCL and WM.
BGB-16673 is an orally available BTK targeting protein degrader from BeiGene's chimeric degradation activation compound (CDAC) platform. It is designed to promote the degradation of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors. BGB-16673 is currently the most advanced BTK protein degrader in clinical development and has received Fast Track Designation from the FDA for treating adult patients with R/R CLL/SLL and R/R MCL.
Company Transition
BeiGene, which will soon change its name to BeOne Medicines Ltd., continues to focus on developing innovative oncology treatments that are more affordable and accessible to cancer patients worldwide. The company employs more than 11,000 colleagues across six continents and is committed to expanding access to medicines for patients globally.
